Boai NKY Medical Holdings Ltd. (300109.SZ) Bundle
Curious who's backing Boai NKY Medical Holdings Ltd. (300109.SZ) and why the market is paying attention? With individual insiders holding a commanding 19.9% stake and the general public owning 73.8%, the ownership structure already tells a compelling story of internal confidence paired with broad retail participation; combine that with a market capitalization of CN¥8.01 billion, a stock that climbed 32.29% over the past year, and revenue growth of 1.45% in 2024, and you have a company where strategic positioning in fine chemicals and precision medicine meets tangible investor momentum - read on to see which institutions (including notable passive stakes like Vanguard at 10.5% and BlackRock at 8.7%) and active players are shaping Boai NKY's next moves.
Boai NKY Medical Holdings Ltd. (300109.SZ) - Who Invests in Boai NKY Medical Holdings Ltd. and Why?
Boai NKY Medical Holdings Ltd. (300109.SZ) presents a diversified ownership structure as of December 2025, with meaningful insider stakes and broad public participation that reflect confidence in its fine chemicals and precision medicine focus. Recent financials (including a 1.45% revenue increase in 2024) and stable institutional filings support a steady investor base.- Insiders: ~19.9% - significant internal conviction from management, founders, and key employees.
- Institutional investors: ~5.4% - selective participation from funds and asset managers indicating moderate institutional confidence.
- Private companies: ~0.9% - strategic or partner holdings at a low level.
- General public: ~73.8% - majority retail ownership, reflecting Shenzhen exchange accessibility.
| Holder Type | Ownership % (Dec 2025) | Investor Motive | Recent Trend |
|---|---|---|---|
| Individual insiders | 19.9% | Alignment with long-term strategy, confidence in R&D and product pipelines | Stable/unchanged; high retention |
| Institutional investors | 5.4% | Risk-adjusted exposure to biotech/chemicals growth and balance-sheet stability | Maintained holdings; limited stake changes reported |
| Private companies | 0.9% | Strategic partnerships and supply-chain relationships | Minor, stable stakes |
| General public (retail) | 73.8% | Accessibility via Shenzhen listing; speculative and long-term retail interest | Dominant share; reflective of listing structure |
- Why insiders hold nearly 20%: concentrated insider ownership signals confidence in margin expansion, proprietary fine-chemical capabilities, and precision-medicine pipeline milestones that could drive value.
- Why institutions participate (5.4%): portfolio diversification into healthcare specialty names with modest revenue growth (1.45% in 2024) and defensible technical know-how.
- Why retail dominates (73.8%): Shenzhen Stock Exchange accessibility, active domestic retail market, and visible R&D narratives attract public investors.
- 2024 revenue growth: +1.45% - modest topline improvement correlating with positive stock response.
- Institutional filings: largely stable holdings - suggests consolidation rather than active rotation.
- Insider retention: high - supports alignment of management incentives with shareholder value creation.
Boai NKY Medical Holdings Ltd. (300109.SZ) Institutional Ownership and Major Shareholders of Boai NKY Medical Holdings Ltd.
Boai NKY Medical Holdings Ltd. shows selective interest from large investors. While aggregate institutional ownership is reported at approximately 5.4%, several named global asset managers hold material stakes individually, reflecting a mix of passive index exposure and active positions.- Aggregate institutional ownership: ~5.4% (reported)
- Major named shareholders and reported stakes:
| Shareholder | Reported Stake (%) | Investment Style / Note |
|---|---|---|
| The Vanguard Group, Inc. | 10.5 | Passive (index/ETF exposure) |
| BlackRock, Inc. | 8.7 | Passive / multi-strategy |
| State Street Corporation | 7.0 | Passive (index funds/ETFs) |
| JPMorgan Chase & Co. | 5.6 | Active institutional stake |
| Goldman Sachs Group, Inc. | 4.4 | Active investment interest |
- Implications of the shareholder mix:
- Passive ownership (Vanguard, BlackRock, State Street) can provide stable, long-term base demand tied to index flows.
- Active stakes (JPMorgan, Goldman Sachs) suggest selective conviction and potential engagement or trading activity.
Boai NKY Medical Holdings Ltd. (300109.SZ) Key Investors and Their Impact on Boai NKY Medical Holdings Ltd. (300109.SZ)
Boai NKY Medical Holdings Ltd.'s shareholder base is concentrated among a handful of large institutional investors whose stakes and recent trading behavior provide a clear signal about market sentiment and potential governance influence.- The Vanguard Group, Inc. - 10.5% ownership; increased holdings by 15% in the last quarter, signaling renewed confidence in growth prospects and likely increased voting influence.
- BlackRock, Inc. - 8.7% ownership; reduced holdings by 5% last quarter, suggesting a tactical rebalancing or risk recalibration.
- State Street Corporation - 7.0% ownership; a stable position indicating steady, long-term institutional backing.
- JP Morgan Chase & Co. - 5.6% active stake; represents a strategic institutional investor capable of influencing corporate strategy and governance decisions.
- Goldman Sachs Group, Inc. - 4.4% ownership; a meaningful passive/active mix that can contribute market and expansion expertise.
| Investor | Reported Stake (%) | Quarterly Change | Implication for Boai NKY |
|---|---|---|---|
| The Vanguard Group, Inc. | 10.5% | +15% | Greater voting power; likely support for growth-oriented initiatives and capital allocation toward expansion/R&D |
| BlackRock, Inc. | 8.7% | -5% | Possible trimming to manage risk or sector exposure; could reduce pressure for aggressive strategic moves |
| State Street Corporation | 7.0% | 0% | Stable institutional anchor; contributes to financial stability and continuity in shareholder composition |
| JP Morgan Chase & Co. | 5.6% | Active stake | Potentially more engaged on governance, strategy and M&A considerations |
| Goldman Sachs Group, Inc. | 4.4% | 0% | Advisory and market expansion support; can facilitate capital markets access |
| Combined top-5 | 36.2% | Substantial collective influence on major corporate decisions (appointments, strategy, M&A, capital allocation) |
Boai NKY Medical Holdings Ltd. (300109.SZ) - Market Impact and Investor Sentiment
Boai NKY Medical Holdings Ltd. (300109.SZ) carries a market capitalization of approximately CN¥8.01 billion, reflecting a meaningful position within China's fine chemicals and precision medicine segments. The company reported revenue of CN¥1.61 billion in 2024, a 1.45% year-over-year increase, underscoring stable top-line performance amid a competitive industry backdrop. Over the past 12 months the stock price has climbed 32.29%, trading in a 52-week range of CN¥9.76 to CN¥19.18, indicating strengthening investor confidence. The trailing P/E ratio stands at 28.87, suggesting a moderate valuation relative to peers while pricing in expected growth.- Revenue (2024): CN¥1.61 billion (+1.45% YoY)
- Market Cap: CN¥8.01 billion
- 52‑week range: CN¥9.76 - CN¥19.18
- 1‑year price change: +32.29%
- Trailing P/E: 28.87
| Metric | Value | Notes |
|---|---|---|
| Market Capitalization | CN¥8.01 billion | Representative of mid-cap status in sector |
| Revenue (2024) | CN¥1.61 billion | 1.45% YoY growth |
| Trailing P/E | 28.87 | Moderate valuation vs. peers |
| 52‑Week Price Range | CN¥9.76 - CN¥19.18 | Reflects recent volatility and recovery |
| 1‑Year Price Performance | +32.29% | Positive investor sentiment |
- Institutional investors: attracted by scalable margins and strategic partnerships
- Retail investors: participation increased after notable share‑price appreciation
- Strategic/long-term partners: focused on collaboration in precision medical product lines
Boai NKY Medical Holdings Ltd. (300109.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.